Results 221 to 230 of about 2,012,724 (325)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Partially Successful Adrenal Vein Sampling With and Without Cross-Sectional Imaging in Primary Aldosteronism Subtyping. [PDF]

Hypertension
Vibhatavata P, Mermejo LM, Zhao L, Shields JJ, Turcu AF.   +4 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Frameless robotic stereotactic brain biopsy workflow with CT-MRI fusion and CT-to-fluoroscopy registration: Step-by-step technical note and early experience. [PDF]

Brain Spine
Taravilla-Loma M, Rodríguez-Domínguez V, Sánchez CV, Gandía-González ML, Guerrero AI.   +4 more
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Simulation of aircraft flights with turbulence and icing conditions. [PDF]

Sci Data
Dampeyrou C, Ghienne M, Tschannen V, Dion JL.   +3 more
europepmc   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

State of Ohio Adversity and Resilience (SOAR) study protocol: a comprehensive, multimodal, family-based, longitudinal observational investigation of risk and resilience in mental health and substance use disorders. [PDF]

BMJ Open
King AP, Langenecker S, Gorka SM, Turner J, Wang L, Wastler H, Gonzalez M, Christian LM, Keck C, Olsen R, Kim H, Klamer B, Fernandez S, Adler C, Andari E, Barrenger SL, Bonfine N, Bozzay M, Brown SL, Browning C, Burkhouse K, Carter K, Cecil K, Coifman KG, Coccaro E, Crawford TN, Cronin C, Delbello M, Duchemin AM, Evans SW, Flask C, Forney KJ, Grant L, Gunstad J, Hershberger PJ, Hoskinson KR, Klein C, Koenig S, McVoy M, Miller PK, Moreno J, Nelson EE, Nesse R, Nguyen C, Nomaguchi K, Paolella A, Perdomo E, Odden C, Sajatovic M, McCullumsmith R, Trauth J, Tso I, Wang X, Weinandy JT, Westrick-Payne KK, Winbush G, Wymbs BT, Xie H, Gavazzi S, Huerta TR, Maynard-Wentzel G, Kraguljac N, Phan KL.   +62 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

A cross-sectional study on hypertension and diabetes care cascade and prevalence of noncommunicable diseases risk factors in Tamil Nadu: rationale and methods. [PDF]

MethodsX
Ramalingam A, Chadwick J, Kriina M, Neelavanan MD, Govindan A, R D, Venkatasamy V, Devasagayam E, Joseph S, Madhusoodanan S, Kangusamy B, Ramaswamy S, Govindasamy E, I K, Paparaju AK, D C, Kumar D, Rajasekar D, Duraisamy A, Subramaniam S, Viswanathan V, K K, Selvam JM, S ST, S V, Thamburaj AA, Palanaiandi SK, Kaur P, Murekhar M.   +28 more
europepmc   +1 more source